Abstract |
Experimental autoimmune neuritis (EAN) is an animal model for Guillain-Barré syndrome (GBS). Intravenous immunoglobulins ( IVIg) are an effective treatment for GBS, but their mechanism of action is not well understood. Here we tested whether IVIg treatment, a potent modulator of proinflammatory assaults, reduces inflammation in EAN. The evaluation of IVIg treatment failed to demonstrate a salutary effect in different models of EAN. IVIg appears not to suppress the acute inflammatory insult on the peripheral nerve, but may have beneficial long-term effects not looked for in the present investigation.
|
Authors | U Enders, K V Toyka, H P Hartung, R Gold |
Journal | Journal of neuroimmunology
(J Neuroimmunol)
Vol. 76
Issue 1-2
Pg. 112-6
(Jun 1997)
ISSN: 0165-5728 [Print] Netherlands |
PMID | 9184640
(Publication Type: Journal Article)
|
Chemical References |
- Immunoglobulins, Intravenous
|
Topics |
- Animals
- Female
- Immunoglobulins, Intravenous
(therapeutic use)
- Neuritis, Autoimmune, Experimental
(therapy)
- Polyradiculoneuropathy
(therapy)
- Rats
- Rats, Inbred Lew
|